Cargando…

Antibody blockade of CD96 by distinct molecular mechanisms

The molecular interactions of mouse CD96 to CD155 ligand and to two surrogate antibodies have been investigated. Biophysical and structural studies demonstrate that CD96 forms a homodimer but assembles as 1:1 heterodimeric complexes with CD155 or with one of the surrogate antibodies, which compete f...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lee, Peter S., Chau, Bryant, Barman, Ishita, Bee, Christine, Jashnani, Aarti, Hogan, Jason M., Aguilar, Barbara, Dollinger, Gavin, Rajpal, Arvind, Strop, Pavel
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Taylor & Francis 2021
Materias:	Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8489928/ https://www.ncbi.nlm.nih.gov/pubmed/34595996 http://dx.doi.org/10.1080/19420862.2021.1979800

Ejemplares similares

Biophysical characterization of PVR family interactions and therapeutic antibody recognition to TIGIT
por: Diong, SJ J., et al.
Publicado: (2023)

Impact of Drug Conjugation on Thermal and Metabolic Stabilities of Aglycosylated and N-Glycosylated Antibodies
por: Yamazoe, Sayumi, et al.
Publicado: (2022)

Improved therapeutic index of an acidic pH-selective antibody
por: Lee, Peter S., et al.
Publicado: (2022)

Structures of mouse and human GITR–GITRL complexes reveal unique TNF superfamily interactions
por: Wang, Feng, et al.
Publicado: (2021)

Design and characterization of mouse IgG1 and IgG2a bispecific antibodies for use in syngeneic models
por: Wang, Feng, et al.
Publicado: (2019)

The neonatal Fc receptor (FcRn) binds independently to both sites of the IgG homodimer with identical affinity
por: Abdiche, Yasmina Noubia, et al.
Publicado: (2015)

Humanization of a strategic CD3 epitope enables evaluation of clinical T-cell engagers in a fully immunocompetent in vivo model
por: Zorn, Julie A., et al.
Publicado: (2022)

Targeting CD96 overcomes PD-1 blockade resistance by enhancing CD8+ TIL function in cervical cancer
por: Wang, Yumeng, et al.
Publicado: (2022)

Eurographics '96
por: Bell, Gavin
Publicado: (1996)

CD14; lymphocyte antigen 96 (LY96; MD2)
Publicado: (2010)

Determining the Binding Affinity of Therapeutic Monoclonal Antibodies towards Their Native Unpurified Antigens in Human Serum
por: Bee, Christine, et al.
Publicado: (2013)

TIGIT blockade enhances functionality of peritoneal NK cells with altered expression of DNAM-1/TIGIT/CD96 checkpoint molecules in ovarian cancer
por: Maas, Ralph Ja, et al.
Publicado: (2020)

Mass measurement of the neutron-deficient $^{96}$Cd with ISOLTRAP
por: Mougeot, Maxime
Publicado: (2023)

CD96 as a Potential Immune Regulator in Cancers
por: Feng, Shikai, et al.
Publicado: (2023)

RN765C, a low affinity EGFR antibody drug conjugate with potent anti-tumor activity in preclinical solid tumor models
por: Wong, Oi Kwan, et al.
Publicado: (2018)

Coming of Age: CD96 Emerges as Modulator of Immune Responses
por: Georgiev, Hristo, et al.
Publicado: (2018)

Preclinical Characterization of Relatlimab, a Human LAG-3–Blocking Antibody, Alone or in Combination with Nivolumab
por: Thudium, Kent, et al.
Publicado: (2022)

CBX8 and CD96 Are Important Prognostic Biomarkers of Colorectal Cancer
por: Song, Xin, et al.
Publicado: (2018)

Immune and Clinical Features of CD96 Expression in Glioma by in silico Analysis
por: Zhang, Qiang, et al.
Publicado: (2020)

Altered expression of CD226 and CD96 on natural killer cells in patients with pancreatic cancer
por: Peng, Yun-Peng, et al.
Publicado: (2016)

CD96 Downregulation Promotes the Immune Response of CD4 T Cells and Associates with Ankylosing Spondylitis
por: Wu, Fengqing, et al.
Publicado: (2022)

Linac96
Publicado: (1996)

COLING '96
Publicado: (1996)

Strings '96
por: Collective
Publicado: (1997)

PADLEP '96
por: Collective
Publicado: (1997)

96 Well, High Throughput Translation
por: Allen, Jason, et al.
Publicado: (2002)

Evaluating Antibody Pharmacokinetics as Prerequisite for Determining True Efficacy as Shown by Dual Targeting of PD-1 and CD96
por: Boch, Christina, et al.
Publicado: (2022)

Fcγ receptor–mediated cross-linking codefines the immunostimulatory activity of anti-human CD96 antibodies
por: Rogel, Anne, et al.
Publicado: (2022)

Hitting the complexity of the TIGIT-CD96-CD112R-CD226 axis for next-generation cancer immunotherapy
por: Jin, Hyung-seung, et al.
Publicado: (2021)

Loss of CD96 Expression as a Marker of HIV-Specific CD8(+) T-Cell Differentiation and Dysfunction
por: Bunet, Rémi, et al.
Publicado: (2021)

Corrigendum: Immune and Clinical Features of CD96 Expression in Glioma by in silico Analysis
por: Zhang, Qiang, et al.
Publicado: (2020)

An Inhibitory Role for Human CD96 Endodomain in T Cell Anti-Tumor Responses
por: Wang, Chelsia Qiuxia, et al.
Publicado: (2023)

Phenotypically distinct helper NK cells are required for gp96-mediated anti-tumor immunity
por: Sedlacek, Abigail L., et al.
Publicado: (2016)

A Novel Blockade CD47 Antibody With Therapeutic Potential for Cancer
por: Lin, Fangzhen, et al.
Publicado: (2021)

Germline-encoded neutralization of a Staphylococcus aureus virulence factor by the human antibody repertoire
por: Yeung, Yik Andy, et al.
Publicado: (2016)

BCL9 regulates CD226 and CD96 checkpoints in CD8(+) T cells to improve PD-1 response in cancer
por: Feng, Mei, et al.
Publicado: (2021)

Deficiency of the CD155-CD96 immune checkpoint controls IL-9 production in giant cell arteritis
por: Ohtsuki, Shozo, et al.
Publicado: (2023)

Conférence : Linac 96
Publicado: (1997)

Conference DAQ '96
Publicado: (1996)

Supercomputing '96 Conference
por: Collective
Publicado: (1996)

Cannot write session to /tmp/vufind_sessions/sess_kq9p04tuqq7jhv87m3th5ego0l